To further explore this potential, our team is conducting a phase Ib/II clinical trial (NCT06742411) evaluating the combination of HBOT with PD‐1 inhibitors and chemotherapy as a first‐line treatment for advanced GC/GEJC. The gene discussed is PDCD1; the disease is gastric cancer.